Keenova Study Suggests Broader Criteria for Peyronie's Disease Treatment
Event summary
- Keenova published a post-hoc analysis in Translational Andrology and Urology on August 3, 2026.
- The study examined whether baseline penile pain influences treatment outcomes for Peyronie's disease using XIAFLEX.
- Findings suggest pain and disease duration should not be the sole determinants of treatment timing.
- XIAFLEX is indicated for adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees.
The big picture
Keenova's study challenges the conventional focus on pain and disease duration in Peyronie's disease management, suggesting a more holistic approach. This aligns with broader industry trends toward personalized medicine and comprehensive patient assessments. The findings could potentially expand the patient pool eligible for XIAFLEX treatment, impacting market dynamics in the urology sector.
What we're watching
- Treatment Guidelines Evolution
- How these findings will influence clinical guidelines for Peyronie's disease treatment.
- Market Positioning
- Whether Keenova can leverage this data to strengthen XIAFLEX's market position.
- Regulatory Scrutiny
- The pace at which regulatory bodies may review or update treatment protocols based on these insights.